Related Experiment Videos

Targeted agents in AML: much more to do

Richard M Stone1

  • 1Adult Leukemia Program, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, D 840 Boston, MA 02115, USA. rstone@partners.org

Best Practice & Research. Clinical Haematology
|March 6, 2007
PubMed

Insights

Targeted therapy shows limited success in acute myeloid leukemia (AML) compared to other cancers. While potential targets exist, current treatments offer modest results, with future hope for improved outcomes in AML therapy.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Targeted therapy has revolutionized cancer treatment in diseases like CML and GIST.
  • Its success relies on identifying specific molecular targets crucial for tumor survival.
  • Acute myeloid leukemia (AML) presents a complex challenge for targeted approaches.

Purpose of the Study:

  • To evaluate the effectiveness of targeted therapy in acute myeloid leukemia (AML).
  • To identify "drugable" molecular targets within AML pathophysiology.
  • To assess the potential for future targeted treatment strategies in AML.

Main Methods:

  • Review of current understanding of AML pathophysiology.
  • Analysis of identified molecular targets in AML.
  • Comparison of targeted therapy success rates across different cancers.

Main Results:

  • Unlike CML and GIST, AML lacks a single validated "Achilles heel" target for current therapies.
  • Potential molecular targets have been identified, but no single agent yields significant remission rates.
  • Early attempts show modest success, indicating potential for future development.

Conclusions:

  • Targeted therapy in AML has not yet achieved the success seen in other malignancies.
  • Further research into AML-specific targets is crucial for developing effective treatments.
  • Nascent successes offer hope for future advancements in AML targeted therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.